Background: Evaluation of the effectiveness and safety of using chlorhexidine 0.02% eye drops developed as a magistral formula in the treatment of Acanthamoeba keratitis.
Method: The medical record of the infected patient was reviewed and the following data were collected: symptoms and signs at the time of diagnosis, treatment instituted, adverse reactions, and both objective and subjective evolution during the process.
Results: The patient was treated from diagnosis with propamidine isethionate (Brolene®) eye drops and chlorhexidine 0.02%. She suffered two reactivation of infection during combination therapy and finally Brolene® was suspended by corneal toxicity, remaining with topical chlorhexidine 0.02% as monotherapy to date.
Discussion: Monotherapy with topical 0.02% chlorhexidine was effective (there was no worsening or reactivation of infection) and well tolerated. In our experience 0.02%, chlorhexidine eye drops have proven to be safe and better tolerated than Brolene®
© 2001-2024 Fundación Dialnet · Todos los derechos reservados